FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3146533948> ?p ?o ?g. }

• W3146533948 endingPage "1140" @default.
• W3146533948 startingPage "1129" @default.
• W3146533948 abstract "BackgroundCurrent treatment for Chagas disease with the only available drugs, benznidazole or nifurtimox, has substantial limitations, including long treatment duration and safety and tolerability concerns. We aimed to evaluate the efficacy and safety of new benznidazole monotherapy regimens and combinations with fosravuconazole, in the treatment of Chagas disease.MethodsWe did a double-blind, double-dummy, phase 2, multicentre, randomised trial in three outpatient units in Bolivia. Adults aged 18–50 years with chronic indeterminate Chagas disease, confirmed by serological testing and positive qualitative PCR results, were randomly assigned (1:1:1:1:1:1:1) to one of seven treatment groups using a balanced block randomisation scheme with an interactive response system. Participants were assigned to benznidazole 300 mg daily for 8 weeks, 4 weeks, or 2 weeks, benznidazole 150 mg daily for 4 weeks, benznidazole 150 mg daily for 4 weeks plus fosravuconazole, benznidazole 300 mg once per week for 8 weeks plus fosravuconazole, or placebo, with a 12-month follow-up period. The primary endpoints were sustained parasitological clearance at 6 months, defined as persistent negative qualitative PCR results from end of treatment, and incidence and severity of treatment-emergent adverse events, serious adverse events, and adverse events leading to treatment discontinuation. Primary efficacy analysis was based on the intention-to-treat and per-protocol populations and secondary efficacy analyses on the per-protocol population. Safety analyses were based on the as-treated population. Recruitment is now closed. This trial is registered with ClinicalTrials.gov, NCT03378661.FindingsBetween Nov 30, 2016, and July 27, 2017, we screened 518 patients, and 210 were enrolled and randomised. 30 patients (14%) were assigned to each treatment group. All 210 randomised patients were included in the intention-to-treat population, and 190 (90%) were included in the per-protocol population. In the intention-to-treat analysis, only one (3%) of 30 patients in the placebo group had sustained parasitological clearance at 6 months of follow-up. Sustained parasitological clearance at 6 months was observed in 25 (89%) of 28 patients receiving benznidazole 300 mg daily for 8 weeks (rate difference vs placebo 86% [95% CI 73–99]), 25 (89%) of 28 receiving benznidazole 300 mg daily for 4 weeks (86% [73–99]), 24 (83%) of 29 receiving benznidazole 300 mg daily for 2 weeks (79% [64–95]), 25 (83%) of 30 receiving benznidazole 150 mg daily for 4 weeks (80% [65–95]), 23 (85%) of 28 receiving benznidazole 150 mg daily for 4 weeks plus fosravuconazole (82% [67–97]), and 24 (83%) of 29 receiving benznidazole 300 mg weekly for 8 weeks plus fosravuconazole (79% [64–95]; p<0·0001 for all group comparisons with placebo). Six patients (3%) had ten serious adverse events (leukopenia [n=3], neutropenia [n=2], pyrexia, maculopapular rash, acute cholecystitis, biliary polyp, and breast cancer), eight had 12 severe adverse events (defined as interfering substantially with the patient's usual functions; elevated alanine aminotransferase [n=4], elevated gamma-glutamyltransferase [n=2], elevated aspartate aminotransferase [n=1], neutropenia [n=3], leukopenia [n=1], and breast cancer [n=1]), and 15 (7%) had adverse events that led to treatment discontinuation (most of these were in the groups who received benznidazole 300 mg daily for 8 weeks, benznidazole 300 mg once per week for 8 weeks plus fosravuconazole, and benznidazole 150 mg daily for 4 weeks plus fosravuconazole). No adverse events leading to treatment discontinuation were observed in patients treated with benznidazole 300 mg daily for 2 weeks or placebo. There were no treatment-related deaths.InterpretationBenznidazole induced effective antiparasitic response, regardless of treatment duration, dose, or combination with fosravuconazole, and was well tolerated in adult patients with chronic Chagas disease. Shorter or reduced regimens of benznidazole could substantially improve treatment tolerability and accessibility, but further studies are needed to confirm these results.FundingDrugs for Neglected Diseases initiative (DNDi).TranslationFor the Spanish translation of the abstract see Supplementary Materials section." @default.
• W3146533948 created "2021-04-13" @default.
• W3146533948 creator A5002866839 @default.
• W3146533948 creator A5003416785 @default.
• W3146533948 creator A5007007569 @default.
• W3146533948 creator A5008768220 @default.
• W3146533948 creator A5010189987 @default.
• W3146533948 creator A5014300609 @default.
• W3146533948 creator A5016038455 @default.
• W3146533948 creator A5017761060 @default.
• W3146533948 creator A5018744039 @default.
• W3146533948 creator A5024914411 @default.
• W3146533948 creator A5025348475 @default.
• W3146533948 creator A5026277687 @default.
• W3146533948 creator A5029205217 @default.
• W3146533948 creator A5033283183 @default.
• W3146533948 creator A5037814267 @default.
• W3146533948 creator A5039064294 @default.
• W3146533948 creator A5040463614 @default.
• W3146533948 creator A5041516138 @default.
• W3146533948 creator A5041752331 @default.
• W3146533948 creator A5041782717 @default.
• W3146533948 creator A5044950114 @default.
• W3146533948 creator A5046263982 @default.
• W3146533948 creator A5047421912 @default.
• W3146533948 creator A5047734723 @default.
• W3146533948 creator A5048920226 @default.
• W3146533948 creator A5058158408 @default.
• W3146533948 creator A5064702901 @default.
• W3146533948 creator A5067193247 @default.
• W3146533948 creator A5071153849 @default.
• W3146533948 creator A5075383103 @default.
• W3146533948 creator A5078094277 @default.
• W3146533948 creator A5083568557 @default.
• W3146533948 creator A5086103829 @default.
• W3146533948 creator A5089240415 @default.
• W3146533948 creator A5089743376 @default.
• W3146533948 creator A5090780969 @default.
• W3146533948 date "2021-08-01" @default.
• W3146533948 modified "2023-10-18" @default.
• W3146533948 title "New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial" @default.
• W3146533948 cites W1901605865 @default.
• W3146533948 cites W1924186013 @default.
• W3146533948 cites W1976268031 @default.
• W3146533948 cites W2039939971 @default.
• W3146533948 cites W2060595374 @default.
• W3146533948 cites W2063503143 @default.
• W3146533948 cites W2076977355 @default.
• W3146533948 cites W2111406316 @default.
• W3146533948 cites W2113628732 @default.
• W3146533948 cites W2117846137 @default.
• W3146533948 cites W2135370680 @default.
• W3146533948 cites W2144299113 @default.
• W3146533948 cites W2147087372 @default.
• W3146533948 cites W2162042226 @default.
• W3146533948 cites W2164957182 @default.
• W3146533948 cites W2168925952 @default.
• W3146533948 cites W2556635462 @default.
• W3146533948 cites W2589928324 @default.
• W3146533948 cites W2784228551 @default.
• W3146533948 cites W2790371978 @default.
• W3146533948 cites W2807532918 @default.
• W3146533948 cites W2885713296 @default.
• W3146533948 cites W2911615502 @default.
• W3146533948 cites W2970664791 @default.
• W3146533948 cites W2991384797 @default.
• W3146533948 cites W3036655543 @default.
• W3146533948 cites W3126487534 @default.
• W3146533948 cites W67775154 @default.
• W3146533948 doi "https://doi.org/10.1016/s1473-3099(20)30844-6" @default.
• W3146533948 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33836161" @default.
• W3146533948 hasPublicationYear "2021" @default.
• W3146533948 type Work @default.
• W3146533948 sameAs 3146533948 @default.
• W3146533948 citedByCount "82" @default.
• W3146533948 countsByYear W31465339482021 @default.
• W3146533948 countsByYear W31465339482022 @default.
• W3146533948 countsByYear W31465339482023 @default.
• W3146533948 crossrefType "journal-article" @default.
• W3146533948 hasAuthorship W3146533948A5002866839 @default.
• W3146533948 hasAuthorship W3146533948A5003416785 @default.
• W3146533948 hasAuthorship W3146533948A5007007569 @default.
• W3146533948 hasAuthorship W3146533948A5008768220 @default.
• W3146533948 hasAuthorship W3146533948A5010189987 @default.
• W3146533948 hasAuthorship W3146533948A5014300609 @default.
• W3146533948 hasAuthorship W3146533948A5016038455 @default.
• W3146533948 hasAuthorship W3146533948A5017761060 @default.
• W3146533948 hasAuthorship W3146533948A5018744039 @default.
• W3146533948 hasAuthorship W3146533948A5024914411 @default.
• W3146533948 hasAuthorship W3146533948A5025348475 @default.
• W3146533948 hasAuthorship W3146533948A5026277687 @default.
• W3146533948 hasAuthorship W3146533948A5029205217 @default.
• W3146533948 hasAuthorship W3146533948A5033283183 @default.
• W3146533948 hasAuthorship W3146533948A5037814267 @default.
• W3146533948 hasAuthorship W3146533948A5039064294 @default.
• W3146533948 hasAuthorship W3146533948A5040463614 @default.
• W3146533948 hasAuthorship W3146533948A5041516138 @default.
• W3146533948 hasAuthorship W3146533948A5041752331 @default.

• next